Share-based Payments

3 Months Ended

Mar. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Payments

Share-based Payments

Share-based Compensation Expense

The following table summarizes share-based compensation expense included within our condensed consolidated statements of income:

	For the Three Months Ended March 31,
(In millions)	2013			2012
Research and development	$	25.2		$	19.7
Selling, general and administrative	34.3			28.8
Subtotal	59.5			48.5
Capitalized share-based compensation costs	(2.3		)	(1.2		)
Share-based compensation expense included in total cost and expenses	57.2			47.3
Income tax effect	(16.6		)	(14.4		)
Share-based compensation expense included in net income attributable to Biogen Idec Inc.	$	40.6		$	32.9

The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:

	For the Three Months Ended March 31,
(In millions)	2013			2012
Stock options	$	0.3		$	0.1
Market stock units	8.5			6.0
Time-vested restricted stock units	27.1			25.8
Performance-vested restricted stock units settled in shares	—			0.1
Cash settled performance shares	20.4			14.8
Employee stock purchase plan	3.2			1.7
Subtotal	59.5			48.5
Capitalized share-based compensation costs	(2.3		)	(1.2		)
Share-based compensation expense included in total cost and expenses	$	57.2		$	47.3

Grants Under Share-based Compensation Plans

The following table summarizes our equity grants to employees, officers and directors under our current stock plans:

	For the Three Months Ended March 31,
	2013	2012
Market stock units	253,000	286,000
Cash settled performance shares	270,000	310,000
Time-vested restricted stock units	638,000	771,000

No performance-vested restricted stock units or stock options were granted during the three months ended March 31, 2013 and 2012. In addition, for the three months ended March 31, 2013, approximately 112,000 shares were issued under our employee stock purchase plan (ESPP) compared to approximately 106,000 shares issued in the prior year comparative period.